Background
Ovarian carcinoma is the second leading cause of cancer-related deaths among
women. Many treatment strategies have been developed; however, the prognosis
is still poor. This study aims to evaluate the immunohistochemical expression of the
serine/threonine-protein kinase B-raf (BRAF) and nuclear factor erythroid 2-related
factor 2 (Nrf2) in serous ovarian tumors and to correlate their expression with
clinicopathological features of the cases.
Materials and methods
This uncontrolled retrospective study was performed on 50 cases: benign (n=10),
borderline (n=12), and malignant serous ovarian neoplasm (n=28). The malignant
serous tumors included nine low-grade cases and 19 high-grade cases. The
immunohistochemical expression of Nrf2 and BRAF was correlated with
clinicopathological features of prognostic importance.
Results
The mean of BRAF expression is increased in borderline but it is almost equal for
low-grade and high-grade carcinoma cases, which was statistically significant
(P |
